Slovakia becomes the final European Union country to be recognized by FDA, and the mutual recognition agreement for inspections of manufacturing sites between the US and the EU is now fully implemented. / read more /
Gilead Sciences gains rights to clinical and preclinical programs in Galapagos' portfolio through a 10-year global research and development collaboration. / read more /
advertisement
Subscribe
Subscribers can enjoy each full issue of Pharm Tech Europe in print, or via Pharm Tech Europe apps.
Novartis, Amgen, and Banner have announced their decision to discontinue the investigation into the BACE1 inhibitor CNP520 (umibecestat) as a preventative therapy for Alzheimer’s disease. / read more /
As drug supply chain security is of paramount importance, could radio-frequency identification solutions provide the optimal solution for pharma companies? / read more /
MHRA has launched a consultation to gain a greater understanding of the potential application of AQbD in pharmacopoeial standards and the future of medicines standards. / read more /
MHRA has issued a drug alert for the Emerade adrenaline auto-injector device, as a result of the device's potential to fail in delivery of the dose due to blockage of the needle. / read more /
Boehringer Ingelheim will combine assets from its cancer immunology portfolio with the KISIMA immunization platform from AMAL Therapeutics. / read more /
Kite, a Gilead company, announced plans to build a new facility for the development and manufacturing of the starting material for the production of cell therapies, viral vectors. / read more /
The Wellcome Global Monitor has demonstrated an overall positive trust in science but some concerns still remain on attitudes on vaccines. / read more /
Today's quality inspection systems for pharmaceutical packaging catch tinier flaws, manage data, and increasingly rely on artificial intelligence to further boost performance. / read more /
The increasing growth in the cell- and gene-therapy markets is inspiring CDMOs to expand their services in this emerging biologic drug arena. / read more /
The editors explore novel technologies for the formulation, manufacture,
purification, and delivery of sterile small- and large-molecule drugs including single-use systems, facilities and equipment, contamination issues, and process analytics.
